The Changing Landscape for HER2+ Advanced Metastatic Breast Cancer

An international perspective pertaining to treatment advances in HER2-positive metastatic breast cancer and how to best apply data from ESMO 2021 into daily practice.

EP. 1: Global Trends in HER2+ MBC

November 8th 2021

Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.

EP. 2: Standard Treatment Approaches in HER2+ MBC

November 8th 2021

A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.

EP. 3: Updated Data From DESTINY-Breast03 in HER2+ MBC

November 15th 2021

Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.

EP. 4: Subgroup Analyses of DESTINY-Breast03 in HER2+ MBC

November 15th 2021

Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.

EP. 5: Managing TRAEs Associated With Novel HER2+ MBC Therapies

November 22nd 2021

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

EP. 6: T-DXd for HER2+ MBC and Interstitial Lung Disease

November 22nd 2021

Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.

EP. 7: Novel Combination Approaches for HER2+ MBC

November 29th 2021

An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.

EP. 8: Updates to HER2CLIMB in HER2+ MBC

November 29th 2021

Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.

EP. 9: Updates in the Management of HER2+ MBC With Brain Metastases

December 6th 2021

Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.

EP. 10: ADCs Under Investigation for HER2+ MBC

December 6th 2021

Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.

EP. 11: Therapeutic Sequencing in HER2+ MBC

December 13th 2021

A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.

EP. 12: Optimizing Therapy in HER2+ MBC Across the Globe

December 13th 2021

A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.

EP. 13: Addressing Treatment Gaps in HER2+ MBC

December 13th 2021

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.